126 related articles for article (PubMed ID: 19695688)
1. The effect of hospital operative volume, residual tumor and first-line chemotherapy on survival of ovarian cancer - a prospective nation-wide study in Finland.
Kumpulainen S; Sankila R; Leminen A; Kuoppala T; Komulainen M; Puistola U; Hurme S; Hiekkanen H; Mäkinen J; Grénman S
Gynecol Oncol; 2009 Nov; 115(2):199-203. PubMed ID: 19695688
[TBL] [Abstract][Full Text] [Related]
2. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.
Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Aghajanian C; Barakat RR; Chi DS
Gynecol Oncol; 2008 Feb; 108(2):276-81. PubMed ID: 18063020
[TBL] [Abstract][Full Text] [Related]
3. The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer.
Rocconi RP; Matthews KS; Kemper MK; Hoskins KE; Huh WK; Straughn JM
Gynecol Oncol; 2009 Aug; 114(2):242-5. PubMed ID: 19447480
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic factors for survival of ovarian epithelial cancers: apropos of 287 cases].
Brun JL; Bouzigon E; Saurel J; Chêne G; Briex M; Brun G; Hocke C
Gynecol Obstet Fertil; 2000 Mar; 28(3):223-31. PubMed ID: 10786403
[TBL] [Abstract][Full Text] [Related]
5. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience.
Leiser AL; Chi DS; Ishill NM; Tew WP
Gynecol Oncol; 2007 Jun; 105(3):657-61. PubMed ID: 17395252
[TBL] [Abstract][Full Text] [Related]
6. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis.
Chang SJ; Hodeib M; Chang J; Bristow RE
Gynecol Oncol; 2013 Sep; 130(3):493-8. PubMed ID: 23747291
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy with carboplatin and taxane compared with single drug carboplatin in early stage epithelial ovarian carcinoma.
Skírnisdóttir I; Lindborg K; Sorbe B
Oncol Rep; 2007 Nov; 18(5):1249-56. PubMed ID: 17914581
[TBL] [Abstract][Full Text] [Related]
8. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
Matsuo K; Bond VK; Eno ML; Im DD; Rosenshein NB
Int J Cancer; 2009 Dec; 125(11):2721-7. PubMed ID: 19530239
[TBL] [Abstract][Full Text] [Related]
9. Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias?
Tanner EJ; Chi DS; Eisenhauer EL; Diaz-Montes TP; Santillan A; Bristow RE
Gynecol Oncol; 2010 May; 117(2):336-40. PubMed ID: 20153027
[TBL] [Abstract][Full Text] [Related]
10. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
[TBL] [Abstract][Full Text] [Related]
11. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).
Wimberger P; Wehling M; Lehmann N; Kimmig R; Schmalfeldt B; Burges A; Harter P; Pfisterer J; du Bois A
Ann Surg Oncol; 2010 Jun; 17(6):1642-8. PubMed ID: 20165986
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic factors analysis in patients with ovarian malignant germ cell tumor treated with fertility-preserving surgery].
Yang ZJ; Wei RJ; Li L
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):898-904. PubMed ID: 23324188
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Wimberger P; Lehmann N; Kimmig R; Burges A; Meier W; Du Bois A;
Gynecol Oncol; 2007 Jul; 106(1):69-74. PubMed ID: 17397910
[TBL] [Abstract][Full Text] [Related]
14. Intensity-modulated whole abdomen irradiation following adjuvant carboplatin/taxane chemotherapy for FIGO stage III ovarian cancer : four-year outcomes.
Rochet N; Lindel K; Katayama S; Schubert K; Herfarth K; Schneeweiss A; Sohn C; Harms W; Debus J
Strahlenther Onkol; 2015 Jul; 191(7):582-9. PubMed ID: 25786589
[TBL] [Abstract][Full Text] [Related]
15. Does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer?
Flynn PM; Paul J; Cruickshank DJ;
Gynecol Oncol; 2002 Sep; 86(3):354-7. PubMed ID: 12217760
[TBL] [Abstract][Full Text] [Related]
16. Drug sensitivity-related benefit of systematic lymphadenectomy during cytoreductive surgery in optimally debulked stages IIIc and IV ovarian cancer.
Isonishi S; Niimi S; Sasaki H; Ochiai K; Yasuda M; Tanaka T
Gynecol Oncol; 2004 Jun; 93(3):647-52. PubMed ID: 15196859
[TBL] [Abstract][Full Text] [Related]
17. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
[TBL] [Abstract][Full Text] [Related]
18. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
[TBL] [Abstract][Full Text] [Related]
19. Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy.
Eisenhauer EL; Tew WP; Levine DA; Lichtman SM; Brown CL; Aghajanian C; Huh J; Barakat RR; Chi DS
Gynecol Oncol; 2007 Aug; 106(2):381-7. PubMed ID: 17509673
[TBL] [Abstract][Full Text] [Related]
20. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
